Baxter Expands Manufacturing Capacity in China

Baxter International, Inc. plans to invest approximately $60 million during the next five years to expand production capacity at its four manufacturing facilities in China to support sales growth in the company’s Medication Delivery and Renal businesses.

“This investment symbolizes Baxter’s strong commitment to meeting local needs for critical products and advancing healthcare in China and across the Asia Pacific region,” said Peter J. Arduini, president of Baxter’s medication delivery business. “It also underscores the importance of this key market in Baxter’s continuing geographic expansion and growth.”

Baxter provides hospitals throughout China with a range of intravenous solutions and specialty products that are used in combination for fluid replenishment, general anesthesia, nutrition therapy, pain management, antibiotic therapy and chemotherapy. The company also serves a growing population of patients within the country with products and services to treat end-stage kidney disease.